Vol. 3 No. 7A (2022): The Effects of Tenofovir, Lamivudine, Dolutegravir (TLD) and Non-TLD on the Viral Load, Weight, and Body Mass Index of People Living with HIV Newly Initiating Antiretroviral Therapy in Cambodia

Vol. 3 No. 7A (2022)

Published June 1, 2022
The Effects of Tenofovir, Lamivudine, Dolutegravir (TLD) and Non-TLD on the Viral Load, Weight, and Body Mass Index of People Living with HIV Newly Initiating Antiretroviral Therapy in Cambodia

 Student’s Abstract

 

Narom Prak*1,2, Sodara Chan1, Yom An1

1- School of Public Health, National Institute of Public Health, Cambodia

2- National Center for HIV/AIDS, Dermatology and STIs (NCHADS)

*Corresponding author: Narom Prak, Email: praknarom3@gmail.com

Articles

Narom Prak, Sodara Chan, Yom An
The The Effects of Tenofovir, Lamivudine, Dolutegravir (TLD) and Non-TLD on the Viral Load, Weight, and Body Mass Index of People Living with HIV Newly Initiating Antiretroviral Therapy in Cambodia